A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. The trials, conducted in Malawi, studied the efficacy of a vaccine against infection with the Streptococcus pneumoniae bacteria.